WallStSmart

DaVita HealthCare Partners Inc (DVA)vsEnhabit Inc. (EHAB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 1205% more annual revenue ($13.84B vs $1.06B). DVA leads profitability with a 5.7% profit margin vs -0.4%. DVA earns a higher WallStSmart Score of 70/100 (B-).

DVA

Strong Buy

70

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 8.0Quality: 4.3
Piotroski: 3/9Altman Z: 1.22

EHAB

Hold

48

out of 100

Grade: D+

Growth: 5.3Profit: 4.0Value: 6.7Quality: 6.0
Piotroski: 5/9Altman Z: 1.71
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DVAUndervalued (+44.9%)

Margin of Safety

+44.9%

Fair Value

$261.59

Current Price

$198.93

$62.66 discount

UndervaluedFair: $261.59Overvalued
EHABUndervalued (+77.5%)

Margin of Safety

+77.5%

Fair Value

$50.06

Current Price

$13.78

$36.28 discount

UndervaluedFair: $50.06Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVA3 strengths · Avg: 8.7/10
Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

PEG RatioValuation
0.628/10

Growing faster than its price suggests

EPS GrowthGrowth
43.5%8/10

Earnings expanding 43.5% YoY

EHAB2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

EPS GrowthGrowth
8667.0%10/10

Earnings expanding 8667.0% YoY

Areas to Watch

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.7%3/10

5.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

EHAB4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

Market CapQuality
$706.40M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-0.5%2/10

ROE of -0.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, PEG Ratio, EPS Growth. PEG of 0.62 suggests the stock is reasonably priced for its growth.

Bull Case : EHAB

The strongest argument for EHAB centers on Price/Book, EPS Growth.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Bear Case : EHAB

The primary concerns for EHAB are Revenue Growth, Altman Z-Score, Market Cap.

Key Dynamics to Monitor

DVA profiles as a value stock while EHAB is a turnaround play — different risk/reward profiles.

EHAB carries more volatility with a beta of 0.96 — expect wider price swings.

DVA is growing revenue faster at 6.0% — sustainability is the question.

DVA generates stronger free cash flow (219M), providing more financial flexibility.

Bottom Line

DVA scores higher overall (70/100 vs 48/100). EHAB offers better value entry with a 77.5% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Enhabit Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Enhabit, Inc. provides home health and hospice services in the United States.

Visit Website →

Want to dig deeper into these stocks?